^{According to the Zhitong Finance App, Kingsley Biotech (01548) issued an announcement. According to the cooperation and licensing agreement between Legend Biotechnology Co., Ltd. (a joint venture of the company and listed on the US NASDAQ Global Select Market in the form of American Depositary Shares) and Janssen Biotech, Inc. (Janssen) on December 21, 2017, CARVYKTI® generated net trade sales of approximately US$710 million for the quarter ended September 30, 2026.}

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.